B. Riley analyst Mayank Mamtani lowered the firm’s price target on Harrow (HROW) to $65 from $69 and keeps a Buy rating on the shares following the Q4 report. The firm believes the “significant headroom” to multi-year volume growth for all three of the company’s brands remains underappreciated, particularly as Harrow’s commercial teams make progress. However, the firm acknowledges Harrow’s quarterly product business “lumpiness.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- Harrow Health’s Strong Financial Performance and Growth Prospects Justify Buy Rating and $57 Price Target
- Harrow Health Reports Strong 2024 Financial Performance
- Closing Bell Movers: Lululemon falls 10% on soft guidance
- Harrow reports Q4 EPS 24c, consensus 13c
- Harrow reports Q4 core EPS 40c, consensus 13c
